STAT: Hepatitis C drugs remain unaffordable in many countries, says WHO study
“In the latest effort to quantify the burden of expensive medicines, a new study found that the cost of two widely used hepatitis C treatments remains out of reach for people in many poor countries and poses a ‘financial and ethical dilemma’ for payers and doctors. In general, current prices are unaffordable and, as a result, poorer countries may be paying higher prices than wealthier nations, according to the study, which appeared on Tuesday in PLOS Medicine and was conducted by World Health Organization officials…” (Silverman, 5/31).